A clinical review of off-label NMN and NR (nicotinamide mononucleotide and nicotinamide riboside) use in adolescents ages 12 to 17, covering the evidence base, safety signals, regulatory status, and what physicians should discuss with families.
What parents and teens need to know before considering NMN or NR supplementation: current evidence, safety gaps, cognitive and athletic performance claims, and when to talk to a physician.
A guide to NMN and NR use in adolescents ages 12 to 17, covering NAD+ biology, evidence gaps, safety considerations, and how to manage the shift to adult care protocols at age 18.
A guide to NMN and NR supplementation in adults aged 65 and older, covering NAD+ biology, trial data, dosing, safety, and what geriatric patients should realistically expect.
A analysis of NMN and NR (nicotinamide mononucleotide and nicotinamide riboside) use in children under age 12, covering NAD+ biology, developmental safety data, regulatory status, and clinical guidance.
Are NMN or NR supplements safe or appropriate for children under 12 attending school and participating in sports? A HealthRX.com clinical review of the evidence, risks, and current medical guidance.
A guide for caregivers managing low-dose oral minoxidil in adults aged 65 and older, covering dosing, fluid monitoring, fall risk, and when to call for help.
A guide to oral minoxidil use in pediatric patients under age 12, covering developmental risks, cardiovascular effects, hypertrichosis, growth concerns, and the very narrow clinical contexts where it may be prescribed.
A deep dive into how semaglutide (Ozempic) affects growth, puberty, bone density, neurodevelopment, and long-term health in adolescents ages 12 to 17, with trial data, dosing guidance, and monitoring protocols.
A guide to transitioning adolescents on Ozempic (semaglutide) from pediatric to adult diabetes or obesity care, covering timing, dosing continuity, insurance, and monitoring protocols.
A guide to semaglutide (Ozempic 0.5 to 2.0 mg) use in adults aged 65 and older, covering efficacy, safety, muscle and bone considerations, cognitive effects, and prescribing guidance from major trials and guidelines.
A guide to semaglutide (Ozempic 0.5 to 2.0 mg) use in adults 65 and older, covering safe physical activity, cognitive engagement, fall risk, muscle preservation, and practical dose management.
A guide to semaglutide (Ozempic) use in geriatric patients aged 65+, covering dose adjustments, safety monitoring, transitional care handoffs, and evidence from SUSTAIN and SELECT trials.
A guide to semaglutide (Ozempic) use in children younger than 12, covering developmental safety signals, regulatory status, trial data, and evidence-based alternatives.
Ozempic (semaglutide 0.5 to 2.0 mg) is not FDA-approved for children under 12. This clinical review covers the current evidence, guideline positions, risks, and the rare circumstances where a pediatric endocrinologist might consider off-label use.
A guide covering how semaglutide (Ozempic) use in children under 12 affects school attendance, physical activity, nutrition, and daily routines, with evidence-based safety guidance.
Ozempic (semaglutide) is not FDA-approved for children under 12. This evidence-based guide explains the clinical field, transition planning considerations, and what to expect when a pediatric patient moves into adult GLP-1 care.
A clinical review of bremelanotide (PT-141) off-label use in pediatric patients under age 12, covering the regulatory status, pharmacology, safety data, and why prescribing it to young children has no established evidence base.
A guide covering how sirolimus (rapamycin) affects school attendance, physical activity, infection risk, and daily schedules for children under 12 on this immunosuppressant.
A guide to prescribing oral semaglutide (Rybelsus) in patients aged 65 and older, covering dose titration, renal and cardiac considerations, fall-risk, and how to transition geriatric patients smoothly into standard adult-care protocols.
A guide covering what parents, teachers, and caregivers need to know about oral semaglutide (Rybelsus) dosing schedules, nausea management, physical education, and hypoglycemia planning for children under age 12.
A guide on starting, adjusting, and transitioning older adults (65+) from pediatric or young-adult obesity care to liraglutide 3 mg (Saxenda) therapy, with dosing tables, safety data, and evidence-based monitoring protocols.
Saxenda (liraglutide 3 mg) is not FDA-approved for children under 12. This guide explains the current evidence, regulatory status, off-label considerations, and safe injection technique so caregivers can have informed conversations with their child's prescribing physician.
A clinical review of off-label Saxenda (liraglutide 3 mg) use in children under age 12, covering the regulatory status, available trial data, dosing considerations, and safety signals that clinicians and families should understand.
Evidence-based guidance on managing Saxenda (liraglutide 3 mg) in pediatric patients under 12, covering school accommodations, physical activity, nausea timing, hypoglycemia protocols, and communication with teachers and coaches.
A clinical review of sermorelin acetate use in adolescents ages 12 to 17, covering FDA approval status, off-label rationale, dosing, safety signals, and when a specialist referral is required.
A clinical deep-dive into off-label sermorelin use in geriatric patients (65+), covering the evidence base, dosing considerations, safety signals, and what prescribers should know before initiating therapy.
A guide to spironolactone's off-label use for hormonal acne in adolescents ages 12 to 17, covering evidence, dosing, monitoring, and safety considerations.
A guide covering how geriatric patients (65+) using spironolactone for acne can safely manage daily activities, physical exertion, hydration, fall risk, and drug interactions.
A guide to spironolactone use for acne in patients aged 65 and older, covering pharmacokinetics, dosing adjustments, drug interactions, hyperkalemia risk, and how adult-care providers should manage this transition.
A complete caregiver guide to giving spironolactone to children under age 12, including correct dosing, liquid preparation, missed-dose protocols, and when to call the prescriber.
A clinical guide for families and providers on spironolactone use in children under 12 with acne, covering dosing, monitoring, and the step-by-step transition to adult dermatology or endocrinology care.
Review TB-500 evidence for older adults, including the difference from full-length thymosin beta-4 and the limits of dosing, recovery, and safety claims.
Complete caregiver guidance for administering Egrifta (tesamorelin) to children under age 12, including reconstitution steps, injection technique, storage, side effects, and when to call the prescribing clinician.
A clinical guide to transitioning pediatric patients under 12 from tesamorelin-adjacent growth hormone axis therapy into adult endocrine care, covering FDA labeling, GH deficiency guidelines, safety monitoring, and care coordination protocols.
A guide to how testosterone cypionate affects geriatric men (65+), covering bone density, muscle mass, cognition, cardiovascular risk, and safe prescribing thresholds backed by trial data.
Complete caregiver guide to administering testosterone cypionate to children under age 12, including dosing principles, injection technique, storage, and when to call the prescribing physician.
A clinical review of testosterone enanthate off-label use in adolescents ages 12 to 17, covering approved vs. Off-label indications, dosing protocols, safety monitoring, gender-affirming care, and current guideline positions.
A guide to managing testosterone enanthate therapy in adolescents aged 12 to 17, covering academic performance, physical activity, sports eligibility, injection scheduling around school, and safety monitoring.
A clinical guide to managing thymosin alpha-1 (thymalfasin) therapy in adolescents aged 12-17, covering dosing schedules, injection timing around school, sports participation, fatigue patterns, and when to hold a dose.
A guide to thymosin alpha-1 (thymalfasin) use in adults aged 65 and older, covering community programs, physical activity safety, cognitive engagement, and monitoring protocols specific to the geriatric patient.
A guide to topical minoxidil 5% use in geriatric patients, covering efficacy, systemic absorption risks, drug interactions, and practical dosing guidance for adults aged 65 and older.
A guide covering how topical minoxidil 5% is used in children under 12 with alopecia, safety data, dosing considerations, and how to manage the transition to adult care protocols.
A complete caregiver guide to applying tretinoin topically for adolescents aged 12-17, covering dosing, technique, side-effect management, and safety monitoring, prepared by the HealthRX.com Editorial Team.
A guide to tretinoin's developmental impact in adolescents ages 12 to 17, covering skin physiology, acne pathophysiology, efficacy data, safety monitoring, and prescribing considerations for this age group.
A guide to off-label tretinoin use in adolescents ages 12 to 17, covering acne evidence, dosing, safety monitoring, and what pediatric dermatology guidelines actually say.
A guide to how tretinoin affects aging skin in adults 65+, covering pharmacokinetics, efficacy evidence, safety risks, and practical dosing adjustments for geriatric patients.
A guide to off-label tretinoin use in adults 65 and older, covering evidence from key trials, age-related skin changes, dosing adjustments, and safety considerations.
A guide for caregivers administering tretinoin topical to children under 12, covering approved uses, dosing steps, skin prep, side-effect management, and when to call the prescriber.
A guide to tretinoin's developmental safety profile in children under age 12, covering pharmacology, teratogenicity data, systemic absorption, and prescribing guidance.
A guide to tretinoin use in children under 12, covering school routines, sun protection, sports, and daily activity adjustments to keep young skin safe.
A clinically rigorous review of vardenafil off-label use in adolescents aged 12 to 17, covering approved indications, pediatric pharmacokinetics, pulmonary hypertension evidence, safety signals, and prescribing guidance.
A clinical guide to transitioning adolescents ages 12 to 17 taking sildenafil for pulmonary arterial hypertension or other indications into adult care, covering dosing, monitoring, provider handoff, and FDA guidance.
A guide to sildenafil use in geriatric patients (65+), covering pharmacokinetics, cardiovascular considerations, drug interactions, starting doses, and what major trials show about efficacy and safety in older adults.
A clinically detailed guide to off-label semaglutide 2.4 mg (Wegovy) use in adolescents ages 12 to 17, covering trial data, dosing, risks, guideline positions, and how prescribers make individualized decisions.
A comprehensive clinical review of semaglutide 2.4 mg (Wegovy) use in patients aged 65+, covering efficacy, muscle and bone loss risks, nutritional considerations, dose titration, and updated geriatric prescribing guidance.
A clinical guide to semaglutide 2.4 mg (Wegovy) use in adults aged 65 and older, covering efficacy data, safety considerations, muscle and bone loss risks, dose titration, and practical monitoring strategies for older patients.
A clinically detailed guide to starting, continuing, or transitioning onto Wegovy (semaglutide 2.4 mg) in patients aged 65 and older, covering dosing, safety, muscle loss, polypharmacy, and what geriatric guidelines actually say.
Wegovy (semaglutide 2.4 mg) is not FDA-approved for children under 12. This evidence-based guide covers the current data, risks, alternatives, and when off-label use might be considered.
A guide to managing Wegovy (semaglutide 2.4 mg) in children under 12, covering school accommodations, physical activity guidelines, hypoglycemia recognition, and communication strategies for educators and coaches.